Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
Russia’s Lavrov sparks rift at European security meeting
Post Content Post Views: 133
Apex Securities sets Critical Holdings IPO value above initial price
Post Content Post Views: 146
Price analysis 11/24: BTC, ETH, BNB, XRP, SOL, ADA, DOGE, TON, LINK, AVAX
Post Content Post Views: 132
Euro zone factory downturn eased a touch in November -PMI
Post Content Post Views: 138
US ETF assets hit record $7.65 trillion in November -State Street Global Advisors
Post Content Post Views: 129
Cuba stages pro-Palestine march past US embassy in Havana
Post Content Post Views: 143